The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Incubator/Accelerator | Alive

Total Raised


About GamaMabs Pharma

GamaMabs Pharma is a clinical-stage immuno-oncology company developing optimized therapeutic antibodies for the treatment of cancer.

GamaMabs Pharma Headquarter Location

1 place Pierre Potier Oncopole entrée B

Toulouse, 31106,


+33 5 31 61 60 69

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GamaMabs Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GamaMabs Pharma is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

GamaMabs Pharma Patents

GamaMabs Pharma has filed 5 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Clusters of differentiation
  • Experimental cancer drugs
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Clusters of differentiation, Experimental cancer drugs, Monoclonal antibodies, Tyrosine kinase receptors


Application Date


Grant Date



Related Topics

Transcription factors, Clusters of differentiation, Experimental cancer drugs, Monoclonal antibodies, Tyrosine kinase receptors



Latest GamaMabs Pharma News

Neoadjuvant nivolumab plus ipilimumab active in subset of patients with gastric cancers

Jan 20, 2022

André T, et al. Disclosures: André reports honoraria from, a consultant/advisory role with and/or travel, accommodations and expenses from Amgen, Astellas Pharma, AstraZeneca/MedImmune, Bristol Myers Squibb, GamaMabs Pharma, GlaxoSmithKline, Gritstone Oncology, Kaleido Biosciences, MSD Oncology, Pierre Fabre, Roche/Genentech, Seagen, Servier, Tesaro, Transgene and Ventana Medical Systems. Please see the abstract for all other researchers’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact . Back to Healio Neoadjuvant treatment with nivolumab and ipilimumab led to a high rate of pathologic complete response among patients with resectable microsatellite instability-high/mismatch repair deficient gastric cancers, study results showed. The combination also appeared feasible for these patients, according to results of the phase 2 GERCOR NEONIPIGA trial presented during Gastrointestinal Cancers Symposium. Data derived from André T, et al. “Patients with locally advanced esophagogastric junction or gastric adenocarcinoma with deficient mismatch repair have a better prognosis than those with proficient mismatch repair,” Thierry André, MD, professor of medical oncology at Sorbonne University and head of the medical oncology department at Saint-Antoine Hospital in Paris, said during a presentation. “Microsatellite instability-high/mismatch repair deficient [MSI/dMMR] status is predictive of efficacy of immune checkpoint inhibitors . Use of immune checkpoint inhibitors in this population before and/or after radical surgery might improve outcomes.” Rationale and methodology GERCOR NEONIPIGA enrolled 32 patients (median age, 65 years; range, 40-84; 72% men) with resectable MSI/dMMR tumors, including 16 with gastric cancer and 16 with esophagogastric junction adenocarcinoma. Most (n = 22) had initial stage usT3Nx disease. Thierry André Patients received 240 mg nivolumab (Opdivo, Bristol Myers Squibb) , an anti-PD-1 antibody, every 2 weeks for a total of six infusions and 1 mg/kg ipilimumab (Yervoy, Bristol Myers Squibb), an anti-CTLA-4 antibody, every 6 weeks for a total of two infusions, followed by radical surgery about 5 weeks after the last nivolumab dose. Those who had Becker tumor regression grade (TRG) of less than 3 received 480 mg adjuvant nivolumab every 4 weeks for a total of nine infusions. Pathologic complete response rate served as the primary endpoint. Key findings Twenty-seven patients (84%) finished all six neoadjuvant treatment cycles and eight experienced grade 3 to grade 4 treatment-related adverse events during that phase of therapy. All but three patients underwent surgery, including two who refused and had complete endoscopic response with tumor-free biopsies and one who experienced metastatic progression. All 29 patients who underwent surgery a median 35 days after last injection had complete resection. Seventeen patients (59%) had pathologic complete response, four had TRG 1b (< 10% residual tumor per tumor bed), one had TRG 2 (10%-50% of residual tumor) and seven had TRG 3 (50% of residual tumor) per local assessment. Twenty-two patients experienced postoperative general complications, including fistula (n = 6) and pancreatitis (n = 3). With median follow-up of 12 months, 30 patients remained recurrence/progression-free, one had metastatic relapse after six treatment cycles and no surgery, and one died without relapse due to a cardiovascular adverse event 3 days after surgery. “NEONIPIGA raises the question of whether the surgery can be delayed or avoided for some patients with localized MSI/dMMR esophagogastric junction or gastric adenocarcinoma if immune checkpoint inhibitors are effective,” André said. Read more about

GamaMabs Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GamaMabs Pharma Rank

  • Where is GamaMabs Pharma's headquarters?

    GamaMabs Pharma's headquarters is located at 1 place Pierre Potier, Toulouse.

  • What is GamaMabs Pharma's latest funding round?

    GamaMabs Pharma's latest funding round is Incubator/Accelerator.

  • How much did GamaMabs Pharma raise?

    GamaMabs Pharma raised a total of $21.61M.

  • Who are the investors of GamaMabs Pharma?

    Investors of GamaMabs Pharma include Hub HealthTech, iXO Private Equity, Alto Invest, IRDI Capital Investissement, Andera Partners and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.